Beth Eaby‐Sandy
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 4
- Cancer Immunotherapy and Biomarkers 4
- Inflammatory Biomarkers in Disease Prognosis 2
- Pancreatic and Hepatic Oncology Research 1
- Dermatology top 2%
- Chemotherapy-related skin toxicity 3
- Otorhinolaryngology top 5%
-
- Lung Cancer Treatments and Mutations 4
- Lung Cancer Diagnosis and Treatment 2
-
- PI3K/AKT/mTOR signaling in cancer 2
Beth Eaby‐Sandy
12 papers receiving 927 citations
Hit Papers
Peers
Comparison fields: 5 of 70
- Oncology 664
- Dermatology 204
- Otorhinolaryngology 55
- Pulmonary and Respiratory Medicine 332
- Radiology, Nuclear Medicine and Imaging 164
Countries citing papers authored by Beth Eaby‐Sandy
This map shows the geographic impact of Beth Eaby‐Sandy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beth Eaby‐Sandy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beth Eaby‐Sandy more than expected).
Fields of papers citing papers by Beth Eaby‐Sandy
This network shows the impact of papers produced by Beth Eaby‐Sandy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beth Eaby‐Sandy. The network helps show where Beth Eaby‐Sandy may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Beth Eaby‐Sandy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 1 | |
| 2 | 2018 | 32 | |
| 3 | 2018 | 6 | |
| 4 | 2017 | 1 | |
| 5 | 2017 | 9 | |
| 6 | 2017 | 4 | |
| 7 | Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancerbreakdown → | 2017 | 387 |
| 8 | 2017 | 2 | |
| 9 | 2014 | 7 | |
| 10 | 2013 | 177 | |
| 11 | 2012 | 19 | |
| 12 | 2011 | 301 |
About Beth Eaby‐Sandy
Beth Eaby‐Sandy is a scholar working on Transplantation, Dermatology and Oncology, having authored 12 papers that have together received 946 indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Lung Cancer Treatments and Mutations (4 papers), Chemotherapy-related skin toxicity (3 papers), Inflammatory Biomarkers in Disease Prognosis (2 papers), Lung Cancer Diagnosis and Treatment (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers) and Pancreatic and Hepatic Oncology Research (1 paper). The work is most often cited by research in Oncology (664 citations), Dermatology (204 citations) and Otorhinolaryngology (55 citations). Beth Eaby‐Sandy has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Mario E. Lacouture, Alexandre Chan, Jane Bryce, Joel B. Epstein, René‐Jean Bensadoun, Barbara A. Murphy, Milan J. Anadkat, Corey J. Langer, Tracey L. Evans and Rebecca Wong. Their work appears in journals such as Journal of Thoracic Oncology, Supportive Care in Cancer, Cancer, Seminars in Oncology Nursing and Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.